Flow cytometric analysis demonstrated a correlation between the anti-tumor potency of the treatment and the percentage of CD45+ immune cells at the tumor site, in which tumors from combination-treated mice were present with a higher fraction of CD45+ cells compared to untreated mice (~70% increase). This evidence concerns the gene PTPRC and neoplasm.